TABLE OF CONTENTS:
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION 15
2.2 SCOPE OF THE STUDY 15
2.3 ASSUMPTIONS & LIMITATIONS 15
2.3.1 ASSUMPTIONS 15
2.3.2 LIMITATIONS 15
2.4 MARKET STRUCTURE 16
3 RESEARCH METHODOLOGY
4 MARKET DYNAMICS
4.1 INTRODUCTION 26
4.2 DRIVERS 27
4.2.1 RISING AMNIOTIC MEMBRANE TRANSPLANTATIONS 27
4.2.2 RAPID GROWTH IN THE GERIATRIC POPULATION 27
4.2.3 INCREASING RESEARCH ACTIVITIES 28
4.3 RESTRAINTS 28
4.3.1 RISING HEALTHCARE COST 28
4.3.2 STRINGENT REGULATORY POLICIES 28
4.4 OPPORTUNITIES 29
4.4.1 ENTERING DEVELOPING ECONOMIES 29
4.4.2 INCREASING AWARENESS ABOUT THE ADVANTAGES OF AMNIOTIC MEMBRANE TRANSPLANT 29
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 30
5.1.1 R&D 30
5.1.2 MANUFACTURING 30
5.1.3 DISTRIBUTION & SALES 30
5.1.4 POST-SALES MONITORING 31
5.2 PORTER'S FIVE FORCES ANALYSIS 31
5.2.1 BARGAINING POWER OF SUPPLIERS 31
5.2.2 BARGAINING POWER OF BUYERS 32
5.2.3 THREAT OF NEW ENTRANTS 32
5.2.4 THREAT OF SUBSTITUTES 32
5.2.5 INTENSE RIVALRY 32
5.3 INVESTMENT OPPORTUNITIES 33
5.4 PRICING ANALYSIS 33
6 GLOBAL AMNIOTIC MEMBRANE MARKET, BY TYPE
6.1 OVERVIEW 34
6.2 CRYOPRESERVATION AMNIOTIC MEMBRANE 35
6.3 LYOPHILIZED AMNIOTIC MEMBRANE 36
7 GLOBAL AMNIOTIC MEMBRANE MARKET, BY APPLICATION
7.1 OVERVIEW 37
7.2 SURGICAL WOUNDS 38
7.3 OPHTHALMOLOGY 39
7.4 STEM CELL BIOLOGY 39
7.5 REGENERATIVE MEDICINE 40
7.6 PRENATAL DIAGNOSIS 41
7.7 OTHERS 41
8 GLOBAL AMNIOTIC MEMBRANE MARKET, BY END USER
8.1 OVERVIEW 42
8.2 HOSPITAL & CLINICS 43
8.3 AMBULATORY SURGICAL CENTERS 44
8.4 RESEARCH CENTERS AND LABORATORY 45
8.5 OTHERS 45
9 GLOBAL AMNIOTIC MEMBRANE MARKET, BY REGION
9.1 OVERVIEW 46
9.2 AMERICAS 48
9.2.1 NORTH AMERICA 50
9.2.2 LATIN AMERICA 54
9.3 EUROPE 55
9.3.1 WESTERN EUROPE 57
9.3.2 EASTERN EUROPE 65
9.4 ASIA-PACIFIC 67
9.4.1 JAPAN 69
9.4.2 CHINA 70
9.4.3 INDIA 71
9.4.4 SOUTH KOREA 72
9.4.5 AUSTRALIA 73
9.4.6 REST OF ASIA-PACIFIC 74
9.5 MIDDLE EAST & AFRICA 75
9.5.1 MIDDLE EAST 77
9.5.2 AFRICA 78
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION 79
10.2 COMPANY SHARE ANALYSIS 79
11 COMPANY PROFILES
11.1 APPLIED BIOLOGICS 81
11.1.1 COMPANY OVERVIEW 81
11.1.2 FINANCIAL OVERVIEW 81
11.1.3 PRODUCTS/SERVICES OFFERED 81
11.1.4 KEY DEVELOPMENTS 81
11.1.5 SWOT ANALYSIS 81
11.1.6 KEY STRATEGIES 82
11.2 AQUAMED 83
11.2.1 COMPANY OVERVIEW 83
11.2.2 FINANCIAL OVERVIEW 83
11.2.3 PRODUCTS/SERVICES OFFERED 83
11.2.4 KEY DEVELOPMENTS 84
11.2.5 SWOT ANALYSIS 84
11.2.6 KEY STRATEGIES 84
11.3 INTEGRA LIFESCIENCES 85
11.3.1 COMPANY OVERVIEW 85
11.3.2 FINANCIAL OVERVIEW 85
11.3.3 PRODUCTS/SERVICES OFFERED 86
11.3.4 KEY DEVELOPMENTS 86
11.3.5 SWOT ANALYSIS 86
11.3.6 KEY STRATEGIES 87
11.4 SKYE BIOLOGICS INC. 88
11.4.1 COMPANY OVERVIEW 88
11.4.2 FINANCIAL OVERVIEW 88
11.4.3 PRODUCTS/SERVICES OFFERED 88
11.4.4 KEY DEVELOPMENTS 88
11.4.5 SWOT ANALYSIS 89
11.4.6 KEY STRATEGIES 89
11.5 MIMEDX 90
11.5.1 COMPANY OVERVIEW 90
11.5.2 FINANCIAL OVERVIEW 90
11.5.3 PRODUCTS/SERVICES OFFERED 90
11.5.4 KEY DEVELOPMENTS 91
11.5.5 SWOT ANALYSIS 91
11.5.6 KEY STRATEGIES 91
11.6 AMNIOX MEDICAL, INC. 92
11.6.1 COMPANY OVERVIEW 92
11.6.2 FINANCIAL OVERVIEW 92
11.6.3 PRODUCTS/SERVICES OFFERED 92
11.6.4 KEY DEVELOPMENTS 92
11.6.5 SWOT ANALYSIS 93
11.6.6 KEY STRATEGIES 93
11.7 KATENA PRODUCTS, INC. 94
11.7.1 COMPANY OVERVIEW 94
11.7.2 FINANCIAL OVERVIEW 94
11.7.3 PRODUCTS/SERVICES OFFERED 94
11.7.4 KEY DEVELOPMENTS 94
11.7.5 SWOT ANALYSIS 95
11.7.6 KEY STRATEGIES 95
11.8 HUMAN REGENERATIVE TECHNOLOGIES, LLC 96
11.8.1 COMPANY OVERVIEW 96
11.8.2 FINANCIAL OVERVIEW 96
11.8.3 PRODUCTS/SERVICES OFFERED 96
11.8.4 KEY DEVELOPMENTS 96
11.8.5 SWOT ANALYSIS 96
11.8.6 KEY STRATEGIES 96
11.9 AMNIO TECHNOLOGY, LLC 97
11.9.1 COMPANY OVERVIEW 97
11.9.2 FINANCIAL OVERVIEW 97
11.9.3 PRODUCTS/SERVICES OFFERED 97
11.9.4 KEY DEVELOPMENTS 97
11.9.5 SWOT ANALYSIS 97
11.9.6 KEY STRATEGIES 98
11.10 OSIRIS THERAPEUTICS, INC. 99
11.10.1 COMPANY OVERVIEW 99
11.10.2 FINANCIAL OVERVIEW 99
11.10.3 PRODUCTS/SERVICES OFFERED 99
11.10.4 KEY DEVELOPMENTS 100
11.10.5 SWOT ANALYSIS 100
11.10.6 KEY STRATEGIES 100
12 APPENDIX
12.1 REFERENCES 101
12.2 RELATED REPORTS 101
